Evidence map›Paper›PMID 26029101›Full record

ReviewFrontiers in aging neuroscience2015

A succinct overview of virtual reality technology use in Alzheimer's disease.

Rebeca I García-Betances, María Teresa Arredondo Waldmeyer, Giuseppe Fico, María Fernanda Cabrera-Umpiérrez

Erratum issuedAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 73 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Rebeca I García-BetancesLife Supporting Technologies (LifeSTech), ETSI Telecomunicaciones, Universidad Politécnica de Madrid , Madrid , Spain.
María Teresa Arredondo WaldmeyerLife Supporting Technologies (LifeSTech), ETSI Telecomunicaciones, Universidad Politécnica de Madrid , Madrid , Spain.
Giuseppe FicoLife Supporting Technologies (LifeSTech), ETSI Telecomunicaciones, Universidad Politécnica de Madrid , Madrid , Spain.
María Fernanda Cabrera-UmpiérrezLife Supporting Technologies (LifeSTech), ETSI Telecomunicaciones, Universidad Politécnica de Madrid , Madrid , Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We provide a brief review and appraisal of recent and current virtual reality (VR) technology for Alzheimer's disease (AD) applications. We categorize them according to their intended purpose (e.g., diagnosis, patient cognitive training, caregivers' education, etc.), focus feature (e.g., spatial impairment, memory deficit, etc.), methodology employed (e.g., tasks, games, etc.), immersion level, and passive or active interaction. Critical assessment indicates that most of them do not yet take full advantage of virtual environments with high levels of immersion and interaction. Many still rely on conventional 2D graphic displays to create non-immersive or semi-immersive VR scenarios. Important improvements are needed to make VR a better and more versatile assessment and training tool for AD. The use of the latest display technologies available, such as emerging head-mounted displays and 3D smart TV technologies, together with realistic multi-sensorial interaction devices, and neuro-physiological feedback capacity, are some of the most beneficial improvements this mini-review suggests. Additionally, it would be desirable that such VR applications for AD be easily and affordably transferable to in-home and nursing home environments.

Indexed as

Alzheimer’s diseasecognitive rehabilitationmild cognitive impairmentvirtual environmentsvirtual reality

Identifiers

PMID26029101
PMCPMC4428215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.